3CC | Third Culture Capital

3CC | Third Culture Capital Research Investment Thesis 3CC (Third Culture Capital) is a physician-led, immigrant-founded, diversity-certified venture capital fund investing at the intersection of equity and care delivery. Founded in 2021 and headquartered in Boston, Massachusetts, the fund invests exclusively in healthcare innovation with a unique lens: backing founders who bring cross-cultural perspectives and lived experiences addressing structural health inequities. The fund's thesis centers on the belief that healthcare innovation and modern care delivery have the potential to lift up humanity, and they specifically target founders who don't fit the traditional mold and embody "Third Culture" principles. Core Investment Philosophy The fund deploys capital across three dimensions: Human Capital : Providing strategic guidance, operational support, and access to a deep network of healthcare insiders, clinicians, and operators Financial Capital : Stage-appropriate checks ranging from $250K to $1M depending on the company modality Cultural Capital : Leveraging cross-cultural insights and diverse perspectives to solve healthcare problems 3CC explicitly targets founders with: Unique life experiences from transnational or multicultural upbringings ("Third Culture Kids") Cross-cultural or cross-disciplinary approaches to healthcare innovation Lived experience in healthcare gaps and structural inequities they're solving Global mindset with proven plans for market entry (particularly US expansion for international founders) Third Culture Principles The fund's investment criteria emphasizes founders who: Exist at the intersection of clinical expertise and technical expertise Combine experience and talent with expertise and execution Balance purpose and potential with leadership and vision Navigate multiple environments, customs, and cultural norms Demonstrate situational awareness and intellectual flexibility Often speak multiple languages and show deep empathy Investment Strategy Stage Focus : Early-stage, pre-seed and seed-stage companies Pre-Seed: $250K-$500K for teams with initial proof of concept Seed: $500K-$1M for teams with traction and early customers Stage-appropriate checks based on company modality (software vs. substrate/bio) Check Size : $250K to $1M Preference for leading rounds Strong syndicate building capability through healthcare network Healthcare Modalities : The fund invests across all healthcare sectors, with particular emphasis on: Digital health and virtual care solutions Care delivery innovation and patient experience Biotech and therapeutics ("substrate" companies combining biology and data) Software-based healthcare platforms Solutions addressing care access and health disparities Maternal health and specialized care populations Rare disease and neurological therapeutics Healthcare operational systems and payments Problem Categories : Solutions must address one or more of: Improve patient outcomes Lower costs Improve patient experience of care Improve provider experience of care Portfolio Companies (16+) The fund has invested in diverse healthcare companies across digital health, biotech, and care delivery: Notable Portfolio: AcousticaBio - Advanced manufacturing for life sciences Aviwell - Microbiome discovery platform for food sustainability Binkey - Healthcare payment processing solutions Boswell - Caring for underserved families Ciba Health - Virtual care platform (led Series B round in 2023) Docosan - Patient health data management Helm Health - Health plan enablement Intus Care - Predictive analytics for senior care (Series B 2021: $16.5M) KeyWise - Digital brain health tracking Lime Health - Digital patient care guidance Mahmee - Parenthood care services Pragma Bio - Gut-immune axis drug development SimpliFed - Infant nutrition innovation (most recent investment, May 2025) Voiceitt - Accessible speech recognition for people with disabilities ($4.7M in 2022) Vitaa - Physician-targeted patient matching Zuri Fertility - Digital fertility clinic Team & Leadership Julien L. Pham, MD, MPH - Founder & Managing Partner Over 15 years of leadership in clinical settings and emerging medical technology Board-certified Internal Medicine physician and Nephrologist NIH research funding recipient at Harvard with publications in basic, translational science, and health policy Led gene therapy biotech (Genprex) through IPO (NASDAQ: GNPX) in 2018 as President & COO through 2020 Co-founder and CMO of RubiconMD (Series C backed by Deerfield Management and Optum Ventures) - digital health eConsults platform Harvard Medical School faculty, Massachusetts General Hospital staff Launched RHINNO innovation lab at Mass General and served on founding committee of Harvard Medical School's iHub Personal angel investor in 7+ early-stage companies MD University of Washington, MPH Harvard Chan School of Public Health Christine Hsieh, PhD - Operating Partner MIT-trained scientist turned founder/CEO with expertise in deep technology, data, and strategic vision Chief Strategy and Research Officer at DayToDay Health (digital care management, acquired by Babylon Health) Founder and CEO of Salubris Analytics (behavior change for chronic care) Harvard-MIT Division of Health Sciences and Technology doctorate with independent research funding Developed bioimaging and neuroimaging technologies at Mass General and Mass Eye & Ear MIT Media Lab research on tangible interfaces Entrepreneur in Residence at MIT Board of Directors, HealthTech Build (Boston-based nonprofit) BS Physics/Cell Biology/Neuroscience Rutgers; PhD Harvard-MIT HST; Harvard Law Executive Education Denise Marks, CPA, MBA - Advisor 25+ years in VC/PE operations and finance Currently CFO of CareQuest Institute for Oral Health (large foundation) Chief Administrative Partner, Chief Compliance Officer, and CFO at SV Health Investors ($3B historical commitments) VP Finance & Administration at CMGI @Ventures Manager, Technology Group at PwC LLP working with early-stage and growth companies Board member: National Venture Capital Association, Shore Country Day School, Dress for Success Boston, Women in Alternative Assets BS Finance Penn State; MS/MBA Accounting Northeastern Ravi Thadhani, MD, MPH - Advisor Chief Academic Officer of Mass General Brigham ($1.8B research enterprise) 25 years in executive academic medical administration, clinical/translational research, medical education Dean for Faculty Affairs and Professor of Medicine at Harvard Medical School Former Vice Dean of Research and Chair of Department of Biomedical Sciences at Cedars Sinai Former Chief of Division of Nephrology at Massachusetts General Hospital Faculty Dean for Academic Programs at HMS; chair MGB Committee on Senior Appointments Standing consultant to FDA's Cardio-Renal Division (2020-2024) Experience developing regulatory and marketing strategies with biotech, diagnostic, and pharma companies Co-founded startup biotech companies; holds several patents including diagnostic for pre-eclampsia MD University of Pennsylvania; MPH Harvard Chan School of Public Health Guy Fish, MD, MBA - Special Advisor 30+ years in healthcare, life sciences, and technology Acting CEO of Next Phase Therapeutics (exosome-based dermatology platform) CEO and board member of Cellanyx (live tumor cell diagnostic) Consultant and VC at Fletcher Spaght for 18 years (Sr. Vice President) Helped launch corporate venture arm, raised and wound down 2 funds ($30M and $100M) Securities analyst at Sanford Bernstein (medical devices) Healthcare consultant at Boston Consulting Group Trustee Advisor Beth Israel Deaconess Medical Center (Boston) Board of Directors: Altarum Institute, Phase Biosciences Board observer: Proteus Digital Health MBA Yale School of Management; MD Yale School of Medicine; AB Biochemistry Harvard College Maria V Lopez-Bresnahan, MD, MBA, FAAN - Advisor Senior biopharmaceutical executive with 25+ years developing treatments for neurologic diseases SVP Translational Medicine and Clinical Development at Voyager Therapeutics VP Clinical Research, Neuroscience at Alkermes VP Neurology Clinical Development at Vertex Pharmaceuticals (Phase 1 through registration) Head of Neuromuscular Clinical Research at Pfizer's Rare Disease Research Unit Therapeutic Area Head for Neuroscience at Pfizer's Medicines Development Group Leadership roles at Merck Serono (CNS drug development) SVP and Global Head Medical and Scientific Affairs at inVentiv Health Clinical Scientific Advisory Board member: SYTE.bio (DNA/RNA therapeutics) Founding Venture Partner with AccelHUB Venture Partners Fellow American Academy of Neurology BA Yale University; MD NYU School of Medicine; MBA Northeastern University Decision Process & Investment Timeline Process : Partnership-based evaluation with founder story and cross-cultural perspective central to decision-making. Deep network of healthcare insiders leveraged for due diligence and syndicate building. Timeline : Estimated 2-6 weeks for seed stage decisions. Emphasis on founder quality and fit with 3CC's thesis. Investment Approach : Initial founder conversation assessing background, lived experience, and cross-cultural perspective Market sizing and problem validation Clinical/healthcare expertise review when applicable Reference calls with healthcare leaders and potential customers Partnership consensus on founder fit and problem significance Geographic Focus Primary : Boston, Massachusetts (headquarters) and US market Secondary : Global founders with credible US market expansion plans, particularly: Europe (France, Spain, UK) Other international regions Preference for founders with lived experience in US healthcare or clear market entry strategy Lead Tendency 3CC actively leads and co-leads seed rounds, as evidenced by recent Ciba Health Series B leadership. Strong track record of building strong syndicates leveraging healthcare network. Lead Tendency : Leads Recent Activity (2021-2025) 3CC has been actively deploying capital since launch in 2021: Fund Status : Actively deploying, early-stage focus Recent Investments : May 2025: SimpliFed (infant nutrition innovation) 2022-2023: Voiceitt ($4.7M Series B with Cisco Investments) 2023: Ciba Health (led Series B) 2021: Intus Care Series B ($16.5M) Ongoing: Support and follow-on capital for portfolio companies Notable Press : Extensive coverage in healthcare and entrepreneur media; Founder & Managing Partner Julien Pham frequently featured in healthcare innovation discussions. Warm Intro Requirements The firm accepts cold outreach but values founder story and cross-cultural fit. Warm introductions from network strongly preferred, particularly from: Healthcare leaders Prior portfolio company founders Healthcare insiders in their network Academic medical centers Founder Preferences 3CC seeks founders who: Have unique cultural and cross-disciplinary perspectives Demonstrate lived experience in healthcare gaps they're solving Bring clinical expertise combined with technical/operational capability Show deep empathy and adaptation to multiple environments Have international or multicultural backgrounds Possess operational execution experience Are building solutions with clear healthcare impact metrics Represent underrepresented perspectives in healthcare innovation Historical Context Founded in 2021 by Dr. Julien Pham with support from a diverse advisor network, 3CC emerged from observation that healthcare innovation disproportionately benefits from narrow founder backgrounds. The firm's thesis specifically seeks to correct this by backing founders whose unique perspectives, lived experiences, and cross-cultural fluency position them to identify and solve healthcare challenges differently. The diversity-certified status and strong commitment to equity in healthcare innovation sets the firm apart in the VC landscape. Summary 3CC | Third Culture Capital is a purpose-driven, physician-led seed-stage VC firm with a distinctive thesis focused on backing uniquely qualified founders bringing cross-cultural perspectives to healthcare innovation. The firm combines deep clinical expertise, operational capability, and an extensive healthcare network to provide value beyond capital. With a team of accomplished physicians, operators, and healthcare entrepreneurs, 3CC is well-positioned to identify category-defining healthcare companies solving structural inequities and care delivery challenges.